Preexisting or therapy-induced mutations in relapsed acute lymphoblastic leukemia?

Paul S Gaynon^{1

2}, Etan Orgel^{1

2}, Lingyun Ji^{2

3}

Affiliations

¹ Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA; and.
² Keck School of Medicine and.
³ Department of Preventive Medicine, University of Southern California, Los Angeles, CA.

Free article

Comment

Paul S Gaynon et al. Blood. 2020.

Free article

. 2020 Nov 5;136(19):2233-2235.

doi: 10.1182/blood.2020005258.

Paul S Gaynon^{1

2}, Etan Orgel^{1

2}, Lingyun Ji^{2

3}

¹ Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA; and.
² Keck School of Medicine and.
³ Department of Preventive Medicine, University of Southern California, Los Angeles, CA.

No abstract available

Comment in

Therapy-induced mutagenesis in relapsed ALL is supported by mutational signature analysis.
Brady SW, Ma X, Zhou BS, Pui CH, Yang JJ, Zhang J. Brady SW, et al. Blood. 2020 Nov 5;136(19):2235-2237. doi: 10.1182/blood.2020008107. Blood. 2020. PMID: 32688387 Free PMC article. No abstract available.

Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
Li B, Brady SW, Ma X, Shen S, Zhang Y, Li Y, Szlachta K, Dong L, Liu Y, Yang F, Wang N, Flasch DA, Myers MA, Mulder HL, Ding L, Liu Y, Tian L, Hagiwara K, Xu K, Zhou X, Sioson E, Wang T, Yang L, Zhao J, Zhang H, Shao Y, Sun H, Sun L, Cai J, Sun HY, Lin TN, Du L, Li H, Rusch M, Edmonson MN, Easton J, Zhu X, Zhang J, Cheng C, Raphael BJ, Tang J, Downing JR, Alexandrov LB, Zhou BS, Pui CH, Yang JJ, Zhang J. Li B, et al. Blood. 2020 Jan 2;135(1):41-55. doi: 10.1182/blood.2019002220. Blood. 2020. PMID: 31697823 Free PMC article.